StockData
FibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG) shareholders

FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.90−0.00 (-0.32%)

Close on Nov 17, 2026Market cap $6.00MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
4.3%
0M of 7M shares
Institutional holders
16
3 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $120.49K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Pete O'Heeron6,951,45918.20%13G (passive)Jan 31, 2024
Mike Newlin2,134,8535.58%13G (passive)Aug 9, 2024
Steven Boyd
Joint filing with Armistice Capital, LLC (9.99%)
738,9779.99%13G (passive)Jun 30, 2026
Hamid Khoja630,0097.50%13D (active)Sep 15, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of FBLGValueChange% of portfolio
Cascade Financial Partners, LLC108,8281.63%$103.14K+92,4000.01%
Fund Evaluation Group, LLC51,7940.78%$49.09K–0.00%
Geode Capital Management, LLC30,2990.46%$28.72K+6900.00%
Vanguard Capital Management LLC27,7690.42%$26.33K−39,8960.00%
Qube Research & Technologies Ltd24,3130.37%$23.04KNew0.00%
BlackRock, Inc.18,2380.27%$17.28K−6,4090.00%
Barclays PLC7,2430.11%$6.86KNew0.00%
Vanguard Fiduciary Trust Co6,3800.10%$6.05K–0.00%
Tower Research Capital LLC (TRC)4,7280.07%$4.48K+4,2680.00%
Osaic Holdings, Inc.2,4040.04%$2.28K+2,2500.00%
Royal Bank of Canada1,5220.02%$1.00K+1,3360.00%
UBS Group AG1,0730.02%$1.02K−4,6480.00%
Islay Capital Management, LLC1690.00%$160–0.00%
Grove Bank & Trust1000.00%$95New0.00%
Bnp Paribas Arbitrage, Snc640.00%$61−20.00%
Allworth Financial LP130.00%$13–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026160M4.3%3 / 54 / 40M0M
Q1 2026170M3.3%17 / 00 / 00M0M
Q3 202500M0.0%0 / 00 / 10M0M
Q2 202510M0.0%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

5 funds held FBLG in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of FBLGValue% of fundAs of
Vanguard Extended Market Index Fund27,7690.42%$26.32K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund19,5440.29%$22.67K0.00%May 31, 2026
Fidelity Series Total Market Index Fund2,5710.04%$2.98K0.00%May 31, 2026
Fidelity Total Market Index Fund2,2660.03%$2.63K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund1,0990.02%$1.27K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Pete O'HeeronCHIEF EXECUTIVE OFFICER, Director5,958,14789.49%May 4, 2026
Hamid KhojaChief Scientific Officer301,5714.53%Sep 15, 2026
Jason DavisChief Financial Officer70,0001.05%May 4, 2026
Ruben A. GarciaGeneral Counsel180,0002.70%May 4, 2026
Leigh SteinbergDirector––Sep 1, 2026
Kathleen Hallisey RubinsDirector––Jul 16, 2026
Matthew LinkDirector7,5000.11%Jun 23, 2026
Victoria Ninon Olivia NiklasDirector7,5000.11%Jun 23, 2026
Robert E. HoffmanDirector7,5000.11%Jun 23, 2026
Richard C. Cilento Jr.Director93,2251.40%Jun 23, 2026
Stacy Ann CoenDirector7,5000.11%Jun 12, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Hamid Khoja
Chief Scientific Officer
Sep 15, 2026Award+298,508$1.68$501.49K301,571
Hamid Khoja
Chief Scientific Officer
Mar 4, 2026Buy+30,000$0.38$11.40K61,250
Pete O'Heeron
CHIEF EXECUTIVE OFFICER, Director
Mar 4, 2026Buy+15,872$0.38$6.03K5,958,147
Pete O'Heeron
CHIEF EXECUTIVE OFFICER, Director
Mar 3, 2026Buy+18,200$0.41$7.46K5,942,275
Pete O'Heeron
CHIEF EXECUTIVE OFFICER, Director
Mar 2, 2026Buy+17,428$0.35$6.10K5,924,075
Jason Davis
Chief Financial Officer
Mar 2, 2026Buy+70,000$0.41$28.70K70,000
Ruben A. Garcia
General Counsel
Feb 27, 2026Buy+40,000$0.33$13.20K180,000
Ruben A. Garcia
General Counsel
Dec 11, 2025Buy+140,000$0.34$47.60K140,000
Hamid Khoja
Chief Scientific Officer
May 27, 2025Buy+20,000$0.84$16.80K31,250
Pete O'Heeron
Chief Executive Officer, Director
Dec 9, 2024Gift−100,000––5,906,647
Pete O'Heeron
Chief Executive Officer, Director
Dec 3, 2024Gift−50,000––6,006,647
Pete O'Heeron
Chief Executive Officer, Director
Aug 12, 2024Buy+8,500$1.91$16.24K6,056,647
Hamid Khoja
Chief Scientific Officer
Aug 12, 2024Buy+10,000$1.90$19.00K11,250

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
5.02%
0M shares short
Days to cover
3.1
At 0M shares a day
Change since last report
+1.1%
From 0M shares
Short volume, 20 days
46.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of FibroBiologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 29,056 shares on Sep 2, 2026 over the last 90 days.

See a number that looks wrong?